Philips: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 3, 2026, Philips (PHG -0.52%) announced an 8% increase in equipment order intake. For long-term investors, expanding order books signal that health systems are locking into the company’s diagnostic platforms for years to come. Three things management said stand out.
1. Health Systems Are Prioritizing Clinical Value Over Upfront Price
Hospitals are consolidating vendor relationships to streamline operations, giving Philips an advantage in pitching integrated equipment platforms. Management captured market share in North America by replacing long-standing rivals at major hospital networks.
North America was particularly strong as health systems consolidate, purchasing decisions remain primarily driven by clinical differentiation, productivity gains, and long-term strategic value rather than price alone.
— Roy Jakobs, Chief Executive Officer
2. Subscription Models Are Building Predictable Healthcare Revenue
The company is shifting hospital clients away from one-off equipment sales and toward Enterprise Monitoring as a Service (EMaaS), a model in which health systems pay recurring fees for software and hardware. That recurring model helps insulate cash flows from lumpier capital spending cycles.
Our Enterprise Monitoring as a Service business model also continued to scale with revenues nearly doubling year-on-year, demonstrating steady progress in building more recurring and predictable revenue.
— Charlotte Hanneman, Chief Financial Officer
3. Internal Cost Cuts Are Protecting Profit Margins From Inflation
Rising component costs and wage pressure continue to hit healthcare suppliers, but operational savings are offsetting those headwinds. Management pushed its structural cost-reduction program forward, keeping the business on path to reach its long-term profitability targets.
Our productivity program delivered EUR 170 million in savings in Q3, bringing year-to-date savings to EUR 427 million despite pressure from higher cost inflation. We remain on track to achieve our EUR 1.5 billion target by the end of 2028.
— Charlotte Hanneman, Chief Financial Officer
Looking Ahead
Equipment orders are expanding across core healthcare markets, supported by helium-free imaging platforms and integrated software. Management relies on strategic customer partnerships to navigate hospital spending while monitoring procurement changes in China.
Our year-to-date performance keeps us well on track for the full year. Order intake is up 4%. Comparable sales growth is within our full year range at 3.5%, and underlying margins have expanded by 30 basis points despite inflation and tariffs.
— Roy Jakobs, Chief Executive Officer
Disciplined operational execution underpins the multiyear plan for compound annual growth rate, or CAGR, expansion.
Together with our disciplined execution, this keeps us on track to achieve our Capital Markets Day ambitions, mid-single-digit comparable sales growth CAGR over ’26 to ’28 and a mid-teen adjusted EBITA margin by 2028.
— Roy Jakobs, Chief Executive Officer
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.